logo
Arrested anti-abortion protester 'willing to go to jail'

Arrested anti-abortion protester 'willing to go to jail'

Yahoo15-05-2025

A woman who was arrested for taking part in an anti-abortion protest outside of the Queen Elizabeth University Hospital in Glasgow has said she is prepared to go to prison over the offence.
Rose Docherty, 74, became the first person to be arrested and charged under a new law which creates buffer zones outside Scottish abortion clinics in February.
She has rejected a formal warning from the Crown Office - arguing that it was "unjust" - and is waiting to find out what action may now be taken against her.
Doctors at the hospital have previously told BBC Scotland News that the protests, which have been held outside the hospital for nearly 10 years, were upsetting and intimidating for patients and staff.
The Abortion Services (Safe Access Zones) Act prevents any protests or vigils from taking place within 200m (650ft) of 30 clinics around the country.
Anyone who breaks the buffer zones law could be fined up to £10,000 or an unlimited amount in more serious cases.
Woman, 74, charged under abortion protest law
Anti-abortion group starts Lent hospital protests
Ms Docherty was arrested close to the Queen Elizabeth University Hospital (QEUH) on 19 February.
She had been holding a sign that said "Coercion is a crime, here to talk, only if you want".
In her first broadcast interview since the arrest, she said she had "no reason to regret" the incident.
She told BBC's Scotcast that the arrest was an "alarming" and "surreal" experience.
Ms Docherty added: "I don't feel I was breaking the law because I feel this law is an unjust law.
"I was just standing with a sign that was stating a fact that coercion is a crime.
"I was there to speak with people only if they wanted to speak with me. I wasn't approaching anyone, I wasn't behaving in a manner that was intimidating or harassing anyone."
Dr Greg Irwin, a doctor at the QEUH, was pictured confronting a group of protestors in February 2023, saying that they "cause emotional upset to patients, but also to staff members".
He added: "One in three women will make use of abortion healthcare, so judgemental protests at the hospital gates have a real and unpleasant effect, particularly on these staff members.
"But they also affect other staff, like myself, who find it infuriating to know that there are protesters outside the hospital intimidating patients on their way in.
"It's such an unbelievably cruel and unkind thing to do, and it bothers me throughout the protest period."
The anti-abortion protests are often linked to the 40 Days for Life group - although Ms Docherty denied that she was a member of the US-based organisation.
Following her arrest, the Crown Office sent her a letter which contained a formal warning.
It said the procurator fiscal had decided against bringing Ms Docherty before a court and if she accepted the warning she would not be prosecuted.
"I said I wasn't accepting a warning because it's unjust," she said.
"I would be prepared to go to prison. I have no idea what might happen.
"I'm waiting to see what's going to develop from having written back to the procurator fiscal so it's up to them to see what their next step is."
The Abortion Services (Safe Access Zones) Act came into force last September.
It was drawn up by Scottish Green MSP Gillian Mackay, who said women seeking the procedure were subjected to "totally unacceptable abuse and obstruction" outside hospitals.
It is a criminal offence to behave in ways that could influence the decisions of women and staff to access services within the buffer zones.
Stopping women and staff from entering the clinics or otherwise causing alarm, harassment or distress is also an offence.
Gillian Mackay said patients and staff had told her that they still have to pass the protestors when attending the QEUH and "shared similar distress to what we heard during the passage of the bill".
She added: "I think it's appropriate that we take those concerns seriously and the government take a look at whether an extension is appropriate or not."
Ms Docherty denied that she had deliberately sought to be arrested for publicity, despite it taking place just days after US Vice-President JD Vance highlighted the law as an example of free speech is Europe being "in retreat".
When asked about patients or staff feeling intimidated by the protestors, Ms Docherty said: "If they say they feel that way then they must feel that way, I'm not in charge of their feelings.
"But I know that my intention is not to do that, I'm standing peacefully and quietly."
She added: "We know that women have changed their minds because something has given them pause for thought.
"If someone is being influenced, it seems to point to the fact that their mind isn't made up."
She said that moving to another location further from the hospital would make the group less visible, meaning their "offer of help" was less visible.
"People say we should go to the Scottish parliament, but that's not where the help is needed," she added.
A spokesperson for the Crown Office and Procurator Fiscal Service said: "The procurator fiscal has received a report concerning a 74-year-old in relation to an alleged incident on 19/02/2025.
"The report remains under the consideration of the procurator fiscal."
Abortion buffer zones to take effect within weeks
Abortion protests near clinics banned as buffer zones law goes live
Anti-abortion group will not break buffer zones

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Robotic Pet Company Tombot Secures $6.1M Series A Funding to Support Groundbreaking Health and Senior Care Product Line
Robotic Pet Company Tombot Secures $6.1M Series A Funding to Support Groundbreaking Health and Senior Care Product Line

Business Wire

time4 hours ago

  • Business Wire

Robotic Pet Company Tombot Secures $6.1M Series A Funding to Support Groundbreaking Health and Senior Care Product Line

LOS ANGELES--(BUSINESS WIRE)-- Tombot, the robotics company that earned widespread acclaim at CES earlier this year for its lifelike robotic puppy, Jennie, announced today the successful close—and oversubscription—of its $6.1 million Series A funding round. Tombot's flagship product, Jennie, was designed specifically to treat the Behavioral and Psychological Symptoms of Dementia (BPSD) and other health issues. 'Tombot is entering a high-demand, underserved market at the intersection of mental health and assistive technology,' said Tombot CEO and Co-Founder Tom Stevens. 'Over 300 million seniors around the world with dementia and mild cognitive impairment are unable to care for a live animal at a time when they need the companionship of a pet more than ever. Millions of other individuals suffering from mental health adversities are in a similar predicament.' With artistic design by Jim Henson's Creature Shop, and developed with the guidance of clinical experts, patients, and their families, Jennie provides many of the health benefits associated with live animal ownership, such as reduced stress and loneliness. Jennie will be used in private homes, assisted living and memory care communities, and other settings where live animals are not always safe or practical. Covered with sensors to respond to touch, voice commands, movement, and other sensory inputs, Jennie is rechargeable, fully cleanable, and comes with an optional caregiver app to customize behaviors and ease the burden of caregiving. With participation from both new and existing investors, the funding round was led by Caduceus Capital Partners, a Nashville-based team of veteran healthcare investors with a primary emphasis on accelerating growth of early-stage digital health startups. 'We identified the growing need for robotic companions several years ago and believe the market is now on the brink of exponential expansion,' said Dave Vreeland, senior managing partner, Caduceus Capital Partners. 'By 2030, the U.S. is projected to have 73 million seniors – an aging population that will increasingly face challenges related to loneliness, companionship, and chronic disease management. These issues are rapidly surpassing the capacity of human caregivers alone. Tombot is uniquely positioned to lead this emerging sector and drive widespread adoption of robotic companions." 'This investment will be rocket fuel for Tombot,' said Stevens. 'We are most appreciative of our company's Board of Directors for their ongoing guidance, and are especially grateful to Caduceus for recognizing and supporting Tombot's mission of creating robotic animals that transform the daily lives of individuals, families, and communities facing health adversities.' According to Stevens, this milestone investment will be used to expand Tombot's team, finalize engineering, complete regulatory and safety certifications, and prepare its first robotic pet for customer shipments to its more than 16,000 pre-order and waitlist customers. About Tombot Tombot, Inc., established in 2017, designs realistic robotic companion animals for individuals unable to safely or practically care for a live animal. After Tom Stevens' own mother's progressive dementia necessitated the rehoming of her beloved pet dog for safety reasons, Tom launched Tombot. Tombot's flagship product, Jennie, was designed specifically to treat the Behavioral and Psychological Symptoms of Dementia (BPSD). The Tombot founding team built a prior startup into one of the world's largest legal automation companies and was successfully acquired.

Over 44,000 Pounds Of Shrimp Have Been Recalled Due To Listeria
Over 44,000 Pounds Of Shrimp Have Been Recalled Due To Listeria

Yahoo

time4 hours ago

  • Yahoo

Over 44,000 Pounds Of Shrimp Have Been Recalled Due To Listeria

Open any freezer and there's a good chance that you'll find a bag of frozen shrimp. This type of shellfish is delicious in so many dishes, from pasta to salads to tacos. But if you recently purchased a bag of frozen shrimp, you're going to want to check it before cooking. Bornstein Seafoods Inc., a Bellingham, Washington-based company, has recalled 44,550 pounds of shrimp due to possible listeria monocytogenes contamination, according to the FDA. The company says the listeria was found during a routine sampling, but no illnesses have been reported. On June 10, the company announced the recall of Cooked & Peeled Ready-To-Eat Coldwater Shrimp Meat in 1 and 5-pound bags. According to the recall, the product was distributed to both retailers and wholesale distributors in Oregon, California, Washington, and British Columbia of Canada. But it's worth noting that the products could have been distributed beyond these states and provinces. Listeria is a bacteria that can cause listeriosis, which can cause mild to severe symptoms. According to the FDA, mild cases can include symptoms like fever, nausea, vomiting, and diarrhea, while more severe cases can be life-threatening, especially for at-risk groups: those with weakened immune systems, adults over 65, pregnant people, and newborns. To find out if you have recalled shrimp, you'll need to check the UPC codes and lot numbers, which can be found on the bag. A list of affected product can be found here. If you do have recalled product, consumers are urged to return it to the place of purchase for a refund and to direct any questions to Andrew Bornstein at Andrew@ You Might Also Like Insanely Easy Weeknight Dinners To Try This Week 29 Insanely Delicious Vodka Cocktails

FDA clears Neurent Medical's NEUROMARK for chronic rhinitis treatment
FDA clears Neurent Medical's NEUROMARK for chronic rhinitis treatment

Yahoo

time5 hours ago

  • Yahoo

FDA clears Neurent Medical's NEUROMARK for chronic rhinitis treatment

The US Food and Drug Administration (FDA) has granted 510(k) clearance to Neurent Medical's NEUROMARK system for the treatment of individuals with chronic rhinitis. Comprising a single-use, handheld bipolar radiofrequency (RF) device and a reusable console with a graphical user interface, the system is designed to conform to the anatomy of the patient and target nerve-rich regions in the nasal cavity. Its bioimpedance monitoring technology adjusts energy delivery based on the changes in tissue conductivity. This method makes sure treatment is precise by continuously evaluating the conditions of the tissue and adjusting energy flow, thereby increasing therapeutic outcomes. According to the company, the system's real-time feedback and smart algorithmic control are crucial for directing the proper placement of the electrode and ensuring treatment delivery success. Its atraumatic leaflets and flexible haft will aid physicians in accessing challenging nasal cavity areas and increase the treatment coverage, along with the posterior areas of the lateral nasal wall. The system claims to operate by delivering impedance-controlled, low-power RF energy to disrupt parasympathetic nerve signals. This addresses the primary symptoms of chronic rhinitis, which include rhinorrhoea (runny nose) and persistent congestion in the nasal area. With the FDA clearance, the system is set for broader availability in the US market. The Ireland-based company focuses on chronic inflammatory sino-nasal disease treatments. Neurent Medical CEO Brian Shields said: 'We have just completed a highly successful commercial validation phase, positioning the NEUROMARK system at the forefront of chronic rhinitis care. 'During this phase, we collaborated with leading General ENT [ear, nose, and throat] and rhinology specialists across both private practice and academic settings. Their insights were instrumental in shaping this next-generation system. I am incredibly proud of how their feedback translated into meaningful technological improvements.' "FDA clears Neurent Medical's NEUROMARK for chronic rhinitis treatment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store